Aura Biosciences Closes $280.8M Public Offering at Deep Discount, Extends Runway to 2028

summarizeSummary

Aura Biosciences completed a public offering of common stock and pre-funded warrants, raising $280.8 million in net proceeds at a significant discount, which extends its cash runway into the second half of 2028.

check_boxKey Events

• Public Offering Closed

  Aura Biosciences closed its public offering, including the full exercise of the underwriters' option, selling 46,099,650 shares of common stock and 3,800,000 pre-funded warrants.

• Significant Capital Raise

  The company received approximately $280.8 million in net proceeds from the offering, a substantial amount relative to its market capitalization.

• Deep Discount Pricing

  The common stock was offered at $6.00 per share, a significant discount compared to the current market price of $8.5474.

• High Potential Dilution

  The offering, after accounting for a share repurchase, could result in a potential dilution of over 64% if all new shares and warrants were issued.

auto_awesomeAnalysis

Aura Biosciences has officially closed its public offering, securing approximately $280.8 million in net proceeds. This substantial capital raise, which includes the full exercise of the underwriters' option, is critical for the company, especially given the prior 'going concern' warning in its latest 10-K. The offering was priced at $6.00 per share and $5.99999 per pre-funded warrant, representing a deep discount compared to the current market price of $8.5474. While highly dilutive, with a potential dilution of over 64% if all new shares and warrants were issued, the proceeds are earmarked to advance clinical programs and extend the company's cash runway into the second half of 2028. A portion of the proceeds, $39.0 million, was used to repurchase shares from Matrix Capital Management at an even lower price of $5.64 per share, which is a strategic move to reduce a significant holder's stake. This financing provides a vital lifeline, balancing the negative impact of dilution with the necessity of funding operations and clinical development.